AI analysis of liver cancer treatment with combination therapy
Part of Cancer, Digestive system clinical trials.
This study uses artificial intelligence to analyze imaging and tumor data from patients with hepatocellular carcinoma (liver cancer) being treated with a combination of TACE (a minimally invasive procedure), immunotherapy, and targeted therapy. The goal is to better predict which patients will respond well to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of hepatocellular carcinoma (liver cancer)
- At least one measurable tumor inside the liver
- For prospective participants: scheduled to receive TACE combined with immunotherapy and targeted therapy as first-line treatment
- For retrospective participants: have CT or MRI imaging before treatment and complete follow-up records
- No other active cancers (past 5 years or current), and no rare liver cancer subtypes (sarcomatoid or fibrolamellar)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses artificial intelligence to analyze CT and MRI scans of solid tumors. The goal is to better understand how tumors respond to non-surgical treatments, which could help doctors make more personalized treatment decisions.
This Phase 2 study tests whether an artificial intelligence tool can help doctors choose the right dose for treating advanced hepatocellular carcinoma (HCC), a type of liver cancer. It aims to improve safety and effectiveness by matching treatment to you using your liver function, lab results, and treatment course.
This study looks at whether combining a liver-directed procedure called TACE with tiragolumab and targeted therapy works better for people with unresectable liver cancer that has not spread too far. Researchers will use blood and tissue tests to see how well the treatment works.
This trial uses artificial intelligence to help doctors better stage (classify the severity of) and plan treatment for hepatocellular carcinoma, a type of primary liver cancer. Researchers will collect your clinical information and imaging to see if AI can improve decision-making about your care.
This study uses artificial intelligence (AI) to analyze your CT or MRI scans and help predict how well immunotherapy might work for your liver cancer. The goal is to find better ways to match you with the right treatment and improve your outcomes.
This study uses digital scans of your tumor tissue and CT/MRI images to build a computer model that helps predict whether you might need extra treatment (adjuvant therapy) after liver cancer surgery. The goal is to use your own tissue and scan data to personalize follow-up care.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.